RADX — Radiopharm Theranostics Limited

Is RADX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of July 5, 2026

Radiopharm Theranostics Limited (RADX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Biotechnology) last closed at $4.37. The rating moved from Strong Oversold to Oversold on June 26, 2026 and has changed 24 times in the last 90 days.

Public ratingOversold (as of July 5, 2026)
Last close$4.37
Rating changesRating changed 24 times in the last 90 days
Last changeMoved from Strong Oversold to Oversold on June 26, 2026
SectorHealthcare
IndustryBiotechnology

Latest MarketMoodz coverage

Radiopharm Theranostics Eyes Pivotal Path After RAD101 Interim Results2026-03-24

See today's live rating, score and targets

Members see the live hourly rating for RADX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.